α1-Acid glycoprotein (AGP) is a high-glycosylated, negatively charged plasma protein with anti-inflammatory and/or immunomodulatory activities. CD BioGlyco has successfully developed a highly sensitive glyco-biomarker AGP assay platform combining first-class techniques with the experienced research team to provide customers with scientific assistance in glycomics.

AGP

AGP, also known as orosomucoid, is one of the most highly glycosylated proteins in human plasma, exhibiting an abnormally high degree of glycan branching and being one of the plasma proteins with not only di- and tri- antennary, but also tetra- antennary glycans. AGP has a variety of physiological roles, including immunomodulation, binding and transporting of neutral or basic compounds including drugs, maintenance of capillary barrier function, and metabolic regulation. AGP is an acute-phase protein and the concentration of AGP in blood will increase after various states such as cancer, infection, injury and obesity.

Detection of inflammatory biomarkers, including AGP, is usually performed by ELISA or automated immunoturbidimetric methods using serum in a laboratory setting, which are complex and expensive. The development of easier and cheaper alternative quantification methods is important to provide monitoring or prognostic tools for populations at risk of nutritional deficiencies or chronic disease. In addition, an increasing number of studies are focusing on alternatives to blood sampling, containing urine and saliva, to supplement and expand our diagnostic abilities for nutritional and inflammatory biomarkers.

Fig.1 A flow immunoassay method for the quantification of AGP in human serum, urine, and saliva. (Bmga, 2019)

Our Services

CD BioGlyco focuses on developing multiple reliable and detailed assays for glyco-biomarker AGP detection and analysis. The services we provide include but are not limited to:

• We have developed a lateral flow immunoassay (LFIA) that allows minimal sample preparation and rapid detection of AGP concentrations in human serum, urine and saliva.
• We use sandwich enzyme-linked immunosorbent assays (ELISA) to quantify AGP in a variety of complex solutions from plasma to purified AGP.
• AGP glycosylation changes can be analyzed by MS-based methods or lectin-based techniques.
• We analyze AGP directly from " seromucoid" fractions obtained from human plasma without the need for separation of AGP with antibody and affinity chromatography, this method allows high-throughput and site-specific N-glycosylation LC-MS analysis of AGP at the glycopeptide level.

Applications

• Monitoring the severity of the disease
• Prognosis of postoperative complications of gastrointestinal tumors
• Determination of the stage and severity of inflammation
• Diagnostic and prognostic applications for cardiovascular disease, diabetes, and stroke

Advantages of Us

• Well-trained staff and first-class instrument platform
• Accurate and specific detection of glycosylated proteins
• Highly sensitive detection of small amounts of glyco-biomarkers
• Stability and consistency

CD BioGlyco has established highly accurate and stable AGP detection strategies to provide the most diverse portfolio of glycoprotein detection products and services. It is our mission to shorten the research time and ensure the reliability of the results. If you are interested in our services, please contact us for further information.

Reference

1. Bmga, B.; et al. A point-of-care assay for alpha-1-acid glycoprotein as a diagnostic tool for rapid, mobile-based determination of inflammation. Current Research in Biotechnology. 2019, 1:41-48.